LMR Partners’s Moderna MRNA Stock Holding History

LMR Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.7M	Buy	290,000 +79,400	+38%	+$3.7M	0.03%	300
2025 Q4	$6.21M	Sell	210,600 -220,000	-51%	-$5.98M	0.01%	516
2025 Q3	$11.1M	Buy	430,600 +380,600	+761%	+$10.6M	0.05%	294
2025 Q2	$1.38M	Sell	50,000 -40,200	-45%	-$1.06M	0.01%	723
2025 Q1	$2.56M	Buy	90,200 +69,200	+330%	+$2.46M	0.02%	606
2024 Q4	$873K	Sell	21,000 -94,500	-82%	-$4.52M	0.01%	749
2024 Q3	$7.72M	Sell	115,500 -196,600	-63%	-$18.1M	0.06%	268
2024 Q2	$37.1M	Buy	312,100 +272,100	+680%	+$34.4M	0.31%	63
2024 Q1	$4.26M	Buy	40,000 +30,000	+300%	+$3.02M	0.04%	371
2023 Q4	$995K	Sell	10,000 -25,000	-71%	-$2.1M	0.01%	582
2023 Q3	$3.62M	Buy	+35,000	New	+$3.9M	0.04%	309
2023 Q2	–	Sell	-1,157,300	Closed	-$178M	–	1028
2023 Q1	$178M	Buy	+1,157,300	New	+$191M	2.75%	2

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's MRNA Position: Q1 2026 in Review

LMR Partners reduced its Moderna (MRNA) stake by 99% in Q1 2026, selling an estimated $4.81M and leaving 699 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1327.

LMR Partners first reported a position in MRNA in Q3 2020 and has held it in 12 quarters since. The position peaked at $23.4M in Q3 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

LMR Partners held 699 shares of Moderna worth $35.5K as of Q1 2026.
LMR Partners sold 103,068 Moderna shares in Q1 2026, an estimated $4.81M.
Moderna made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1327 holding.
LMR Partners first reported a position in Moderna in Q3 2020 and has held it in 12 quarters since.
LMR Partners's Moderna position peaked at $23.4M in Q3 2024.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.